Comparison of phaeomelanin and its precursor 5-S-cysteinyldopa in the serum of melanoma patients

Melanoma Research

Volumn 13, Issue 4, 2003, Pages 357-363

  Wakamatsu, Kazumasa ^a   Yokochi, Mika ^a   Naito, Akiko ^a   Kageshita, Toshiro ^b   Ito, Shosuke ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

4 Amino 3 hydroxyphenylalanine; 5 S cysteinyldopa; Melanin; Melanoma; Phaeomelanin

Indexed keywords

3 AMINO 4 HYDROXYPHENYLALANINE; 4 AMINO 3 HYDROXYPHENYLALANINE; BIOCHEMICAL MARKER; CYSTEINYLDOPA; MELANIN; PHEOMELANIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; SERUM;

ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTEINYLDOPA; FEMALE; HUMANS; MALE; MELANINS; MELANOMA; MIDDLE AGED; SERUM; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TYROSINE;

EID: 0041702334     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200308000-00004     Document Type: Article

References (24)

1. Ito S, Wakamatsu K, Ozeki H. Chemical analysis of melanins and its application to the study of the regulation of melanogenesis. Pigment Cell Res 2000; 13 (suppl 8):103-109.
2. Wakamatsu K, Ito S, Fujita K. Production, circulation, and excretion of melanin-related metabolites in B16 melanoma-bearing mice. Acta Derm Venereol 1990; 70:367-372.
3. Agrup G, Agrup P, Andersson T, Hafström L, Hansson C, Jacobsson S, et al. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis. Acta Derm Venereol 1979; 59:381-388.
4. Horikoshi T, Ito S, Wakamatsu K, Onodera H, Eguchi H. Evaluation of melanin-related metabolites as markers of melanoma progression. Cancer 1994; 73:629-636.
5. Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res 1997; 57: 5073-5076.
6. Kärnell R, Kågedal B, Lindholm C, Nilsson B, Årstrand K, Ringborg U. The value of cysteinyldopa in the follow-up of disseminated malignant melanoma. Melanoma Res 2000; 10:363-369.
7. Hartleb J, Arndt R. Review. Cysteine and indole derivatives as markers for malignant melanoma. J Chromatogr B 2001; 764:409-443.
8. Meyer T, Hauschild A, Kromminga A, Hartleb J, Arndt R, Christophers E, et al. Clinical evaluation of 5-S-cysteinyldopa testing using a new and optimized detection system as a tumour marker for malignant melanoma. Melanoma Res 2002; 12:471-477.
9. Wakamatsu K, Kageshita T, Furue M, Hatta N, Kiyohara Y, Nakayama J, et al. Evaluation of 5-S-cysteinyldopa as a marker of melanoma progression: 10 years' experience. Melanoma Res 2002; 12:245-253.
10. Ito S, Fujita K. Microanalysis of eumelanin and pheomelanin in hair and melanomas by chemical degradation and liquid chromatography. Anal Biochem 1985; 144:523-536.
11. Wakamatsu K, Ito S, Rees JL. The usefulness of 4-amino-3-hydroxyphenylalanine as a specific marker of pheomelanin. Pigment Cell Res 2002; 15:225-232.
12. Buzaid AC, Ross MI, Balch CM, Spoong S-I, McCarthy WM, Tinoco L, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 1997; 15:1039-1051.
13. Wakamatsu K, Ito S. Improved HPLC determination of 5-S-cysteinyldopa in serum. Clin Chem 1994; 40:495-496.
14. Wakamatsu K, Ito S, Horikoshi T. Normal values of urinary excretion and serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxy-indole-2-carboxylic acid, biochemical markers of melanoma progression. Melanoma Res 1991; 1:141-147.
15. Wakamatsu K, Ito S. Seasonal variation in serum concentration of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in healthy Japanese. Pigment Cell Res 1995; 8:132-134.
16. Nimmo JE, Gawkrodger DJ, O'Docherty CSJ, Going IW, Percy-Robb IW, Hunter JAA. Plasma 5-S-cysteinyldopa as an index of melanogenesis. Br J Dermatol 1988; 118:487-496.
17. Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, et al. Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res 2000; 6:4768-4775.
18. Agrup G, Andersson T, Falck B, Persson K, Rorsman H, Rosengren AM, et al. 5-S-cysteinyldopa in the plasma of melanoma patients and the renal clearance of this amino acid. Acta Derm Venereol 1975; 55:5-6.
19. Sarna T, Menon IA, Sealy RC. Photoinduced oxygen consumption in melanin systems - II. Action spectra and quantum yields for pheomelanins. Photochem Photobiol 1984; 39:805-809.
20. Harsanyi Brinkmann ZP, Post PW, Brinkman JP, Chedekel MR, Deibel RM. Mutagenesity of melanin from human red hair. Experientia 1980; 36:291-292.
21. Rees JL, Flanagan N. Pigmentation, melanocortins and red hair. QJM 1999; 92:125-131.
22. Takasaki A, Nezirević D, Johansson K, Årstrand K, Wakamatsu K, Ito S, et al. Quantitation of 4-amino-3-hydroxyphenylalanine (AHP) and 3-aminotyrosine (AT) in urine. Pigment Cell Res 2002; 15 (suppl 9):85 (abstract).
23. Balabanli B, Kamisaki Y, Murad F. Requirements for heme and thiols for the nonenzymatic modification of nitrotyrosine. Proc Natl Acad Sci USA 1999; 96:13136-13141.
24. Ohshima H, Celan I, Chazotte L, Pignatelli B, Mower HF. Analysis of 3-nitrotyrosine in biological fluids and protein hydrolyzates by high-performance liquid chromatography using a postseparation, on-line reduction column and electrochemical detection: results with various nitrating agents. Nitric Oxide 1999; 3:132-141.